Technology

PDS Biotechnology

$2.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.24%) As of 3:47 PM UTC today

Why Robinhood?

You can buy or sell PDSB and other stocks, options, and ETFs commission-free!

About PDSB

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ. The listed name for PDSB is PDS Biotechnology Corporation Common Stock.

CEO
Frank K. Bedu-Addo
Employees
20
Headquarters
Princeton, New Jersey
Founded
2019
Market Cap
60.93M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
433.74K
High Today
$2.87
Low Today
$2.76
Open Price
$2.84
Volume
52.58K
52 Week High
$4.98
52 Week Low
$0.6153

Collections

PDSB Earnings

-$1.10
-$0.73
-$0.37
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 26, After Hours

You May Also Like

BMTX+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure